Medullary allotransplant in acute myeloblastic leukemia in a child • JML Journal of Medicine and Life

2014, Volume 7, Issue 3, pp 450 – 454

Medullary allotransplant in acute myeloblastic leukemia in a child

Issues

Special Issues

Authors and Affiliations

Buga Corbu V ^*

Glűck R ^**

Arion C ^**

* *"Carol Davila" University of Medicine and Pharmacy, Bucharest

** **“I. C. Fundeni" Pediatrics Clinic, “Carol Davila" University of Medicine and Pharmacy, Bucharest

Correspondence to:Buga Corbu Veronica, MD, PhD student “Carol Davila" University of Medicine and Pharmacy, Bucharest, 8 Eroilor Sanitari Blvd., 050474, Bucharest, Romania, Phone: +40 21 337 31 01

Abstract

Although acute myeloblastic leukemia (AML) is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progresses have been achieved over the last 20 years with an improvement in the long-term survival up to 50-60%. This may be attributed to the intensification of chemotherapy, including the increased use of stem-cell transplantation (HSCT) in well-defined subgroups. Allo-HSCT represents an extremely effective alternative in pediatric AML treatment panel, but its efficiency is limited both by the toxic effects and by the difficulty of finding a matched HLA donor.

Keywords

acute myeloblastic leukemiachildallo-HSCT

Preview

JMedLife-07-450

Download PDF

About this article

PMC ID: 4233458
PubMed ID: 25408774
DOI:

Article Publishing Date (print): 15-09-2014
Available Online: 25-09-2014

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.